

## TRANSLATION

NUCLEOTIDE SEQUENCES THAT ENCODE CORYNEFORM BACTERIA FOR PROTEINS  
PARTICIPATING IN THE BIOSYNTHESIS OF L-SERINE AND METHOD OF  
PRODUCING L-SERINE

5           The invention relates to the nucleotide sequences of  
coryneform bacteria coding for proteins participating in the  
biosynthesis of L-serine and a method of producing L-serine.

10           The amino acid L-serine finds use in the food industry,  
the animal feed industry and the pharmaceutical industry as well as  
in human medicine. In addition it functions as a building block  
for the synthesis of other industrially valuable products like for  
example L-tryptophane from indole and L-serine.

15           It is known that L-serine can be produced by the  
fermentation of a coryneform bacteria strain. So for example a  
strain of *Corynebacterium glycinophilum* can form L-serine from  
glycine and carbohydrates (Kubota K, Kageyama K, Shiro T and  
Okumura S (1971) Journal of General Applications in Microbiology,  
17: 167-168; Kubota K, Kageyama K, Maeyashiki I, Yamada K and  
Okumura S (1972) Journal of General Applications in Microbiology  
20 18:365).

In the conversion of glycine to L-serine, there is here a participation of the enzyme L-serine-hydroxymethyl-transferase (Kubota K and Yokozeki K (1989) Journal of Fermentation and Bioengineering, 67(6): 387 - 390). The strain which is used  
5 however is associated with a reduced L-serine proteolysis which can lead to a reduction in the activity of the enzyme L-serine-dehydratase (Kubota K, Kageyama K, Shiro T and Okumura S (1971) Journal of General Applications in Microbiology, 17: 167-168; Kubota K, (1985) Agricultural Biological Chemistry 49:7-12).

10 Furthermore, L-serine is produced fermentatively from methanol and glycine with the assistance of methylotrophic bacteria like for example *Hyphomicrobium* lines (Izumi Y, Yoshida Tm Nutazaju Ssm Nutsybagu T, Igsguri T, Shiamo M, Miyata A and Tanabe T (1993) Applied Microbiology and Biotechnology, 39: 427-432). In both  
15 cases the amino acid glycine must be introduced as a precursor for the formation of the amino acid L-serine.

20 Furthermore, Coryneform bacteria are known which can produce the L-serine directly from carbohydrates without adding precursors. These lines belong to the *Corynebacterium glutamicum* species which are characterized by the fact that they are for example resistant with respect to the L-serine analog serine-hydroxamate and  $\beta$ -chloroalanine and are subject to undirected mutagenesis (Yoshida H and Nakayama K (1974) Nihon-Nogei-Kagakukaishi 48: 201-208).

In addition, *Brevibacterium flavum* strains are known which by undirected mutagenesis show defects in the L-serine proteolysis, an increased activity of the *serA*-coded 3-phosphoglycerate- dehydrogenase and which overexpress the genes *serB* and *serC* which derive from *Escherichia coli* (EP 0 931833A2). The deregulated *serA* gene which is thus used is recovered from indirect mutagenesis and differs from the wild type gene only by a single replacement. The expression of this gene has the disadvantage that it easily reverts and thus can pass back into the regulated state.

A drawback of earlier known 3-phosphoglycerate dehydrogenases lies in its feed-back inhibition by L-serine, which, for example, reduces the productivity of the microbial production of L-serine. The region which answers for this regulation by L-serine is the C-terminus of the protein. From WO 93/12235, a DNA is known which codes for a 3-phosphoglycerate-dehydrogenase from *E.coli* whose C-terminus is modified by up to 25%, is completely deleted or is subject to an insertion in a specific region so that the L-serine induced inhibition is reduced. This 3-phosphoglycerate dehydrogenase has however only a small activity. An improved L-serine production cannot be obtained with the deregulated 3-phosphoglycerate-dehydrogenase.

The wild type *SerA* sequence is generally known and can be obtained from data bases known in the art to the artisan or seen in

the accompanying sequence protocol in SEQ ID No. 6 of the accompanying sequence protocol.

It is thus an object of the invention to provide features which enable the aforementioned drawbacks to be obviated and which will give rise to an improved production of L-serine or metabolic products derived therefrom, like for example tryptophane. It is thus also an object of the invention to provide nucleic acids coding for a 3-phosphoglycerate-dehydrogenase which, by comparison to naturally available 3-phosphoglycerate-dehydrogenase has a reduced feedback inhibition through L-serine while maintaining the activity. In this connection it is a further object of the invention to provide a 3-phosphoglycerate-dehydrogenase and microorganisms which by comparison with naturally available 3-phosphoglycerate-dehydrogenase or microorganisms with a 3-phosphoglycerate-dehydrogenase, which will have reduced feedback inhibition by L-serine while maintaining the activity. Furthermore, it is an object of the invention to provide an improved method for the production of L-serine.

Starting from the preamble of claims 1, 2, 3, 4 or 5, the objects are attained according to the invention with the features given in the characterizing parts of claims 1, 2, 3, 4 or 5. Furthermore, the objects are attained in accordance with the invention starting with the preamble of claim 9 with the features contained in the characterizing part of claim 9. The objects are,

in addition attained starting from the preamble of claim 10 in accordance with the invention with the features in the characterizing part of claim 10. The objects are also obtained according to the invention starting with the preamble of claim 11 with the features given in the characterizing part of claim 11. The objects are further obtained according to the invention starting from the preamble of claim 20 with the features given in the characterizing part of claim 20. Starting with the preamble of claim 26 the objects are also achieved given in the characterizing part of claim 26. Furthermore, the objects according to the invention starting from the preamble of claim 27 are attained by the features of the characterizing part of claim 27.

With the nucleic acids according to the invention and the polypeptides it is possible directly to obtain a 3-phosphoglycerate dehydrogenase which, by contrast with naturally available nucleic acids or enzymes or nucleic acids or enzymes which are not modified by gene technology, which have no feedback inhibition, while maintaining the 3-phosphoglycerate-dehydrogenase activity. These characteristics are referred to below as "deregulated" collectively. Furthermore, it is possible to prepare microorganisms and provide a process whereby L-serine production has higher yields by comparison to previously known microbial processes.

Further features are given in the dependent claims.

The subject matter of the invention is the preparation of nucleic acids coding for a deregulated 3-phosphoglycerate-dehydrogenase indicated below by PGD and containing a gene sequence *serA* according to SEQ ID No 1, 2, 3, 4 or 5 or an allele, homologue or derivative of these nucleotide sequences which hybridizes therewith. The nucleic acid according to SEQ ID No. 1 which codes for a PGD with a deletion of 197 amino acids at the C-terminus has been found to be particularly advantageous.

The nucleic acids according to the invention are characterized in that they can be isolated from coryneform bacteria, especially of the geneva *Corynebacterium* or *Brevibacterium* and especially preferably from *Corynebacterium glutamicum*. As examples of the culture lines which have been deposited of the wild type coryneform bacteria, there can be mentioned *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium acetoglutamicum* ATCC 15806 and also *Brevibacterium flavum* ATCC 14067. Examples of mutants or production strains which are suitable for producing L-serine are organisms from the group of *arthrobacter*, *pseudomonas*, *nocardia*, *methylobacterium*, *hyphomicrobium*, *alcaligenes* or *klebsiella*. The present invention will be characterized in greater detail based upon the aforementioned bacterial lines but, is not however limited thereto.

The term nucleic acid or nucleic acid fragment is to be understood, in accordance with the present invention, to refer to a polymer of RNA or DNA which is single-stranded or double-stranded and optionally can contain, natural, chemically synthesized, modified or artificial nucleotides. The term DNA polymer includes also genomic DNA, cDNA or mixtures thereof.

Under the term "allele", there is to be understood in accordance with the invention functional equivalents, namely, substantially identically effective nucleotide sequences.

Functionally equivalent sequences are such sequences which in spite of different nucleotide sequences, for example resulting from the degeneration of the genetic code, nevertheless retain the desired functions. Functional equivalents encompass therefore naturally occurring variants of the herein described sequences as well as synthetic nucleotide sequences, for example those produced by chemical synthesis and optionally nucleotide sequences matched to the codon requirements of the host organism.

A functional equivalent will be understood to include especially also natural or synthetic mutations of originally isolated sequences which have the desired function. Mutations include substitutions, additions, deletions, replacements or insertions of one or more nucleotide residues. Included here are also so-called sense mutations which can give rise at the protein

level, for example, to exchange of conserved amino acids which, however, do not lead to any basic change in the activity of the protein and thus are functionally neutral. These include also alterations in the nucleotide sequence which at the protein level  
5 affect the N-terminus of proteins without however significantly detracting from the function of the protein.

The nucleotide sequences encompassed by the present invention include also such nucleotide sequences as can be obtained by modification of the nucleotide sequences resulting in  
10 corresponding derivatives. The goal of such a modification can be, for example, the further localization of the coded sequence contained therein, or for example, also the insertion of further restriction enzyme cutting sites.

In addition, artificial DNA sequences can be the subject  
15 of the present invention as long as they, as described above, possess the desired characteristic. Such artificial DNA sequences can, for example, be those created by means of computer supported programs (molecular modelling) to produce the desired protein or selected by *in vitro* selection. Especially suitable are coded DNA  
20 sequences which have been modeled to produce a polypeptide sequence which can be obtained by the specific codon utilization of the root organism. The specific codon utilization can be readily determined by the skilled artisan in molecular genetic methods by computer.



evaluation of other previously known genes of the organism to be transformed.

The term "homologous sequences" is to be understood, in accordance with the invention, to refer to nucleotide sequences which are complementary to those of the invention and/or which hybridize with them. The term "hybridizing sequence" encompasses, according to the invention, substantially similar nucleotide sequences from the group of DNA or RNA which under stringent conditions known *per se* interact or bind with the aforementioned nucleotide sequences. In this category can be counted also those short nucleotide sequences with a length of for example 10 to 30 and preferably 12 to 15 nucleotides. These include according to the invention, among others, also so-called primers or probes.

The invention also includes the coded regions (structure genes) starting from (5' - or upstream) and/or subsequent (3' - or downstream) sequence regions. Especially included herein are sequence regions with a regulatory function. They can include the regions which influence transcription, RNA stability or RNA processing as well as translation. Examples for the encompassed regulatory sequences are among others, promoters, enhancers, operators, terminators or translation amplifiers.

The subject matter of the invention is in addition a gene structure containing at least one of the aforescribed nucleotide sequences coding for a deregulated PDG as well as for the regulatory sequences operatively linked therewith and which control the expression of the coded sequences in the host cell.

The present invention further comprises a vector containing a nucleotide sequence of the aforescribed type coding for a deregulated PDG or regulatory nucleotide sequences operatively linked therewith as well as additional nucleotide sequences for the selection of transformed host cells, for the replication within the host cell or the integration in the corresponding host cell genome. The vector according to the invention can additionally contain a gene structure of the aforescribed type.

As vectors, those are suitable which can be replicated in coryneform bacteria like for example pZ1 (Menkel E, Thierbach G, Eggeling L, Sahm H., 1989, *Appl Environ Microbiol* 55(3): 684-688, pEKEx2 (Eikmanns et al., *Gene* 102: 93-98 (1991), pVWEx or pXMJ19. Other plasmid vectors can be used in the same way. This enumeration is not however limiting for the present invention.

Utilizing the nucleic acid sequence according to the invention corresponding probes or also primers can be synthesized and used for example to amplify and isolate analogous genes from other microorganisms, preferably coryneform bacteria, with the aid  
5 of the PCR technique.

The present invention also includes a probe for identifying and/or isolating genes coding for proteins participating in the biosynthesis of L-serine whereby these probes are produced starting from the nucleic acid sequence of the  
10 aforescribed type and contain suitable markers for detection. The probes can be a partial segment of a sequence according to the invention, for example a conserved region which for example can have a length of 10 to 30 nucleotides, preferably 12 to 15 nucleotides, which can hybridize under strict conditions  
15 specifically with homologous nucleotide sequences. Numerous suitable markers are known from the literature. The skilled worker is advised to consult, among others, as examples, the Handbook of Gait: Oligonucleotide synthesis: a practical approach (IRL Press, Oxford, UK, 1984) and Newton and Graham: PCT (Spectrum Akademischer  
20 Verlag, Heidelberg, Germany, 1994) or for example the Handbook "The DIG System Users Guide for Filter Hybridization" the firm Roche Diagnostics (Mannheim, Germany) or Liebl et al. (International Journal of Systematic Bacteriology (1991) 41: 255-260).

The subject of the present invention is also a deregulated PGD or a part thereof coded by a nucleic acid sequence according to the invention according to sequence ID No 1, 2, 3, 4 or 5 or a variation thereof of the previously described type. The present invention relates thus to a deregulated PGD with an amino acid sequence according to the SEQ ID No 7, 8, 9, 10 or 11 or a modified form of these polypeptide sequences or isoforms thereof or mixtures thereof. Especially suitable has been found to be 3-phosphoglycerate dehydrogenase with an amino acid sequence according to SEQ ID No 7.

It should be understood that isoforms are enzymes with the same or comparable substrate specificity and effectivity specificities which however have a different primary structure.

Modified forms are understood to be enzymes according to the invention which, upon changes in the sequence, for example at the N-terminus of the polypeptide or in the region with conceived amino acids, retain the function of the enzyme without detriment. These variations can be in the form of amino acid replacements made by methods known *per se*.

The invention also encompasses polypeptides with the function of a deregulated PGD which has its amino acid sequence so altered that it has been desensitized and especially feed-back desensitized by comparison with compounds which are regulator effective and can for example regulate the activity of the metabolic end product L-serine.

The polypeptides according to the invention are characterized that they derive from corynebacterium preferably of the family corynebacterium or brevibacterium and especially preferably of the *Corynebacterium glutamicum* strain. Examples for the line cultures of wild type coryneform bacteria are the *Corynebacterium glutericum* ATCC 13032, the *Corynebacterium acetoglutamicum* ATCC 15806 or *Brevibacterium flavum* ATCC 14067. Examples of the mutants or production line suitable for the production of L-serine are organisms from the group of *Arthrobacter*, *Pseudomonas*, *Nocardia*, *Methylobacterium*, *Hypomycrobium*, *Alcaligenes* or *Klebsiella*. The present invention will be characterized in greater detail by the specification of the aforementioned bacteria lines but is not however limited thereby.

The subject of the present invention is in addition, the translation of at least one of the nucleic acid sequences according to the invention or a part thereof coded for a deregulated PGD, an allele homolog or derivative thereof in a host system. This

translation of DNA in a host cell is effected in accordance with gene-technological methods. As a preferred process here is transformation and especially preferably the translation of DNA by electroporation.

5           A homologous host system has been found to be especially suitable. Under the designation of homologous host systems are to be understood microorganisms which belong to all of the families used. In accordance with the invention under this designation all coryneform bacteria according to the invention are to be understood  
10 in which nucleic acids derived from coryneform bacteria are incorporated. A nucleic acid translation carried out in accordance with this principle results in a transformed microorganism different from the corresponding untransformed microorganism in that it contains additional nucleic acids in accordance with the  
15 invention and correspondingly can be expressed. As an example of a suitable homologous host system, the bacterium *Corynebacterium glutamicum* and preferably the strain ATCC 13032.

20           As the culture medium depending upon the specific requirements, a complex medium like for example LB Medium (T. Maniatis, E.F. Fritsch and J. Sambrook, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989)) or also a Mineral salt medium like for example CGXII-Medium (Keilhauer, C. et al 1993, *J. Bacteriol.*, 175:5593-5603) are suitable.

After corresponding cultivation, the bacterial suspension can be harvested and used for further investigation, for example, by transformation or isolation of the nucleic acid by conventional methods. This procedure can analogously be used also for other coryneform bacterial strains. In that case as the host system, bacteria of the *Corynebacterium* or *Brevibacterium* families are preferred. Within the *Corynebacterium* family, especially the *Corynebacterium glutamicum* species and within the *Brevibacterium* family, especially the *Brevibacterium flavum* species are preferred. The representatives of these families include those strains which have, from their properties been characterized as Wild Types.

Examples of suitable lines of this type are *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium glutamicum* ATCC 19752, *Corynebacterium acetoglutamicum* ATCC 15806, *Corynebacterium acetoglutamicum* ATCC 15806, *Corynebacterium melassecola* ATCC 17965, *Corynebacterium thermoaminogenes* FERM BP-1539, *Brevibacterium flavum* ATCC 14067, *Brevibacterium lactofermentum* ATCC 13869 and *Brevibacterium divaricatum* ATCC 14020 can be mentioned.

In addition, the present invention also includes bacteria strains as host systems which are characterizable as L-serine producing mutants or amino acid production strains. These can be made, for example, starting from wild type lines by classical (chemical or physical) or gene technology methods. Examples of

suitable lines of this type according to the invention are, among others, *Corynebacterium glutamicum* ATCC 21586, *Corynebacterium glutamicum* KY 10150, *Corynebacterium glutamicum* ATCC 13032 $\Delta$ panBC and *Brevibacterium ketoglutamicum* ATCC 21222.

5           In addition such production strains are suitable according to the invention which are known from microbial production methods to the artisan, like for example enterobacteria, bacillaceen or yeast types. The present invention is characterized in greater detail by these exemplary microorganisms but is not  
10           however limited thereby.

          The present invention relates further to a genetically altered microorganism containing in replicatable form a nucleic acid of the aforescribed type in accordance with the invention and which in comparison to the corresponding not genetically  
15           altered microorganism can be expressed in an amplified manner and/or with an increased copy number. The present invention also encompasses a genetically altered microorganism containing in replicatable form a gene structure or a vector of the aforescribed type.

20           The present invention also has as its subject matter a genetically altered microorganism containing a polypeptide according to the invention with the function of a deregulated PGD of the aforescribed type which, in comparison to the orresponding



not genetically altered microorganism has a reduced feedback inhibition or no feedback inhibition by L-serine while maintaining the PGD activity. A genetically altered microorganism according to the invention is characterized further in that it is a coryneform bacterium, preferably of the corynebacterium or Brevibacterium families and especially preferably of the *Corynebacterium glutamicum* or *Brevibacterium flavum* species.

Basically genes can be amplified and then isolated by methods known *per se* like, for example, the polymerase chain reaction (PCR) with the aid of short synthetic nucleotide sequences (primers). The production of the primer used is effected generally based on known gene sequences utilizing homologies in conserved regions of the gene and/or taking into consideration the GC content of the DNA of the microorganism investigated.

A further procedure for isolating coding nucleotide sequences is the complementation of so-called defect mutants of the organism investigated which at least phenotypically show a function loss in the activity of the gene investigated or the corresponding protein. To be understood under "complementation" is the removal of the gene defect of the mutant and substantial reproduction of the original appearance prior to the mutagenesis which creates the functional gene or gene fragment from the microorganism investigated.

A classical mutagenesis process for producing defect mutants is for example the treatment of the bacteria cell with chemicals like, for example, N-Methyl-N-Nitro-N-Nitrosoguanidine or by UV irradiation. Such processes for triggering mutation are in general known and can among others be derived from Miller (A Short Course in Bacterial Genetics, A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria (Cold Spring Harbor Laboratory Press, 1992)) or in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington, D.C., USA, 1981).

The present invention relates also to a method for the microbial production of L-serine whereby at least one of the nucleic acids according to the invention, isolated from a coryneform bacterium, is translated in a host organism and is there expressed, whereby the gene expression and/or the activity of the corresponding coded polypeptide is increased by comparison with the corresponding nongenetically altered microorganism. This genetically altered microorganism is used for the microbial production of L-serin and the correspondingly formed L-serine is isolated from the culture medium.

To produce an enhanced gene expression (overexpression or superexpression), the copy number of the corresponding gene can be increased. In addition, the promotor region and/or regulation region and/or the ribosomal binding site which is located upstream

of the structure gene, can be so altered correspondingly that the expression is effected at higher rates. Expression cassettes work in the same way and can be built in upstream of the structure gene. With inducible promoters it is possible in addition to increase the expression in the course of the fermentation L-serine production. Utilizing features for increasing the life span of the mRNA, the expression is also improved. The gene or gene construct can be integrated and amplified either in plasmids with different copy numbers or in chromosomes. Furthermore the activity of the enzyme itself can be increased or amplified by hindering the proteolysis of the enzyme protein. Alternatively, in addition, an overexpression of the gene involved can be achieved by varying the medium composition and culture conditions.

The artisan will find teachings thereof, in among others Martin et al. (Bio/Technology 5, 137-146 (1987)), in Guerrero et al. (Gene 138, 35-41 (1994)), Tsuchiya and Morinaga (BioRechnology 6, 428-430 (1988)), in Eikmanns et al (Gene 102, 93-98 (1991)), in the European Patent EPS 0 472 869, in US Patent 4,601,893, in Schwarzer and Pühler (Bio/Technology 9,84-87 (1991), in Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in the Patent application WO 96/15246, in Malumbres et al (Gene 134, 15-24 (1993)), in the Japanese publication JP-A-10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58,

191-195 (1998)), in Makrides (Microbiological Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.

The genetically modified microorganism produced in accordance with the invention can be made continuously or discontinuously in a batch process (set cultivation) or in a fed batch or a repeated fed batch process for the purpose of producing the L-serine. A collection of the known cultivation methods is described in the textbook of Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook of Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium used must suffice in a suitable way to satisfy the requirements of the respective strain. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981) as carbon sources, sugar and carbohydrates, like, for example, glucose, saccharose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats like for example soya oil, sunflower oil, peanut oil and coconut oil, fatty acids, like for example palmitic acids, stearic acids and linoleic acid, alcohols like for example glycerin and ethanol and organic acids like for example acetic acid can be used. These substances can be used individually

or as mixtures. As nitrogen sources, organic nitrogen containing compounds like peptones, yeast extracts, meat extracts, malt extracts, maize spring water, soy bean meal and urea or inorganic compounds like ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate can be used. The nitrogen sources can be used individually or as mixtures.

As phosphorous sources, phosphoric acid, potassium dihydrogen phosphate, dicalcium hydrogen phosphate or corresponding sodium-containing salts can be used. The culture medium must in addition contain salts of metals like for example magnesium sulfate or iron sulfate which are necessary for the cultivation. Finally, essential growth elements like amino acids and vitamins are introduced in addition to the above-mentioned substances.

Appropriate precursors can in addition be added. The mentioned additives can be supplied to the culture in the form of a single introduction or can be fed during the cultivation. For pH control of the culture, basic compounds like sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acid compounds like phosphoric acid or sulfuric acid can be introduced in a suitable way. To control the foam development, anti-foaming agents, like for example fatty acid polyglycol esters can be introduced. To maintain the stability of plasmids, appropriate selectively effective substances, for example antibiotics can be supplied to the medium. In order to maintain aerobic conditions,

oxygen or oxygen-containing gas mixtures like for example air can be introduced into the culture. The temperature of the culture is normally between 20°C to 45°C and advantageously 25°C to 40°C. The culturing is carried out for a period sufficient to produce a maximum of L-serine. This goal is normally reached within 10 hours to 160 hours.

The analysis of L-serine formation can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190) or can be carried out by reverse phase HPLC as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

The microorganisms which are the subject of the present invention can make L-serine from glucose, saccharose, lactose, mannose, fructose, maltose, molasses, starch, cellulose or from glycerin and ethanol. It can use the previously described representatives of the coryneform bacteria class. A selection of results from the fermentation which has been given in Table 6. This shows that the genetically altered microorganisms according to the invention give rise to a significantly improved L-serine production with respect to the corresponding nontransformed microorganisms (wild types) or the microorganisms which contain only the vector without the gene insert. In a special embodiment variant of the present invention it is shown that the overexpression of the homologous C-terminal-shortened serA

gene in *C. glutamicum* ATCC 13032DpanBCpZ1serA $\Delta$ 197 gives rise to at least a 40% increase in the L-serine accumulation in the medium by comparison to the control strain (Table 6). Through a corresponding overexpression of other genes which have a positive effect on the L-serine biosynthesis path, a still greater increase in the L-serine production can be expected.

Under amino acid production strains, in the sense of the present invention, *Corynebacterium glutamicum* strains or homologous microorganisms should be understood which are modified by classical and/or molecular genetic methods so that their metabolic flow is amplified in the direction of the biosynthesis of amino acids or their derivatives (metabolic engineering). For example, amino acid production strains can have one or more genes and/or corresponding enzymes which are modified at different and corresponding complex regulated key positions of the metabolic path (bottlenecks) or deregulated. The present invention encompasses therefore all already known amino acid production strains, preferably of the genus of *Corynebacteria* or homologous organisms. Furthermore, such production strains are encompassed in accordance with the invention which enable the skilled worker in the art in analogy with the knowledge from other organisms, especially enterobacteria, bacillaceen or yeast types, to develop commercial methods.

The Figures show exemplary plasmids which have been used as well as a comparison of the primary structure of the PGD and alleles of *serA* created by PCR.

The Figures show:

5           FIG. 1: A comparison of the primary structure of the 3-phosphoglycerate-dehydrogenase (PGD) from the different organisms; the scaling corresponding to the number of amino acids of the corynebacterial PGD; N = amino terminals; C = the carboxy terminals; the clear grey area marked region A indicates the  
10           nucleotide binding sites; the dark grey area marked region B shows the substrate binding site; the black marked region C shows the inhibitor binding site.

          There are two further groups of 3-phosphoglycerate-dehydrogenases which, by way of example, are represented by *E. coli*  
15           (Tobey K.L. and Grant G.A., 1986, J. Biol. Chem., 261: 12179-12183) and *Thermotoga maritima* (Gene Bank Accession Number AE000512). In this connection the protein of the hyperthermophilic bacterium *T. maritima* with a length of 327 amino acids is the shortest while the  
20           3-phosphoglycerate-dehydrogenase from *E.coli* with 410 amino acids has an intermediate length.



FIG. 2: an overview of the allele of *serA* made by means of PCR and which codes for the deregulated PGD shortened at the C terminal. Illustrated is the *serA* gene region of the wild type and the deletion construct according to the invention. The light, dark and black marked regions correspond to the definitions as in FIG. 1.

FIG. 3: Plasmid vector pZ1*serA*

FIG. 4: Plasmid vector pZ1*serA*Δ79

FIG. 5: Plasmid vector pZ1*serA*Δ188

FIG. 6: Plasmid vector pZ1*serA*Δ197

FIG. 7: Plasmid vector pZ1*serA*Δ205

FIG. 8: Plasmid vector pZ1*serA*Δ211

#### Exemplary Embodiments

1. Targeted Deregulation of the 3-Phosphoglycerate Dehydrogenase of *C. glutamicum*

a) Computer supported amino acid sequence - comparison of the 3-phosphoglycerate-dehydrogenase of *corynebacterium glutamicum* with 3-phosphoglycerate-dehydrogenase from other organisms

Initially a strategy for the construction of a deregulated 3-phosphoglycerate-dehydrogenase was developed. The sequence of the *serA* gene, which coded for the 3-phosphoglycerate-

dehydrogenase of *C. glutamicum*, from the patent data bank was used  
Nakagawa, S., Mizogukchi, H., Ando, S., Hayashi, M., Ochiai, K.,  
Yokoi, H., Tateishi, N., Senoh, A., Ikeda, M. and Ozaki, A. Patent:  
EP 1108790-A 7064 20 Jun 2001; KYOWA HAKKO KOGYO CO., LTD. (JP);  
5 Pompejus, M., Kroeger, B., Schroeder, H., Zelder, O. and  
Haberhauer, G. Patent: WO 0100843-A 167 04-JAN 2001; BASF  
AKTIENGESELLSCHAFT (DE)).

The polypeptide chain derived from the *serA* gene (SEQ ID  
No. 12) of *Corynebacterium glutamicum* was compared with the  
10 corresponding 3-phosphoglycerate-dehydrogenase from the data bank  
(gene bank). It showed that the 3-phosphoglycerate-dehydrogenase  
from the *C. glutamicum* like that from *Mycobacterium tuberculosis*  
(gene bank accession No. AL123456) and several other bacteria  
*Bacillus subtilis* (Sorokin, A., Azevedo, V., Zuimstein, E.,  
15 Galleron, N., Ehrlich, S.D. and Serror, P., Microbiology 142 (Pt  
8), 2005-2016 (1996)) and *Aquifex aeolicus* (GenBank-Accession-  
Number AE000657) with 500 amino acids is unusually long. In this  
group of enzymes are counted also the 3-phosphoglycerate-  
dehydrogenase from animals like rats (Achouri Y., Rider M.H., Van  
20 Schaftingen E. and Robbi M., 1997, Biochem J., 323:365-370) and  
Mensch (Cho HM, Jun Dy, Bae MA, Ahn JD, Kim YH., 2000, Gene  
245(1):193-201) as well as plants (z. B. *Arabidopsis thaliana*; Ho  
CL, Saito K., 2001, Amino Acids. 20(3):243-59).

The analysis of the x-ray structure of the *E. coli* enzyme indicated that it is comprised of three functional domains: a nucleotide binding domain (amino acids 108 to 294) for the binding of NAD/H, a two part substrate binding domain (amino acids 7-107 and 295-336) to which the 3-phosphoglycerate binds as well as a C-terminal regulatory domain (amino acids 337-410) which accounts for the allosteric binding of the L-serine (Schuller DJ, Grant GA, Banaszak LF., 1995, Nature Struct. Biol. Vol 2 1:69-76).

The amino acid sequence comparison of the 3-phosphoglycerate-dehydrogenase types indicated that they differed substantially in the length of the C-terminal regulatory domain (FIG. 1).

A cluster analysis of the 3-phosphoglycerate-dehydrogenase, which was known from the completely sequenced genome, indicated that in spite of the difference in the C-terminus, all of these proteins were part of a family of orthologs, that is that they had a common evolutive origin although they had developed differently in different species.

b) Construction of Alleles of the *serA*-Gene of *C. glutamicum* by means of PCR which code for C-terminal-shortened 3-phosphoglycerate-dehydrogenase proteins

Five different mutations of the 3-phosphoglycerate-dehydrogenase of *C. glutamicum* were produced which had deletions of different lengths at the C terminal (FIG. 2). The construction of the deletion mutant is carried out in the same manner as the isolation of the wild type *serA*- gene by means of PCR. For this purpose, a PCR primer (*serA*-f: 5'-TCTAGAGCCGGAGACGTGAATAAAAT-3') is produced, the homologue being to a region 240 bp prior to the start codon of the gene to encompass the entire promoter region. This primer is used for all constructs and carries at the 3' end a cutting site for the restriction enzyme XbaI. For the amplification of the complete *serA* gene, a second reverse complementary primer is selected which lies 199 bp behind the stop codon and carries a *Bam*HI restriction site (*serA*-r: 5' GGATCCGACTGGTGAGGGTCAAGTCC-3').

The expected PCR product has a length of 2040 bp. To produce the deletion, a reverse complementary primer is selected which lies in the gene region and carries a restriction site for *BAM*HI. The primer *serA* $\Delta$ 211-r (5'-GGATCCTTAACCGGAAACGTTACAGC-3') lies 956 bp behind the start codon so that a PCR product with a length of 1196 bp results. The last 211 amino acids of the 3-phosphoglycerate-dehydrogenase are cut off. The deletion lies generally in the region of the assumed transition from the substrate binding domain to the regulatory domain (compare FIGS. 1 and 2). The primer *serA* $\Delta$ 205-r (5'-GGATCCTTACTCTTCGCCCACGCGACC-3') lies 974 bp behind the start codon and the expected PCR product has

a length of 1214 bp. The C terminal deletion in this case amounts to 204 amino acids and the protein terminates behind the amino acid glutamate at position 325. The undirected exchange of this amino acid to lysine produces in *C. glutamicum* a deregulation of the 3-phosphoglycerate-dehydrogenase (EP 0 931 833). Both deletions lie in a region in which the deletion ( $\Delta$ 209 amino acids) of rat protein has been produced. Achouri Y., Rider M.H., Van Schaftingen E. and Robbi M., 1997, Biochem J., 323-365-370. Both primers *serA* $\Delta$ 197-r (5'-GGATACCTTAAGCCAGAATCCATCCACACAG-3') and *serA* $\Delta$ 188-r (5'-GGATCCTTACTTGCCAGCAAGAAAAGACC-3') lie 998 bp or 1025 bp behind the ATG and find themselves upstream from the transition from the substrate binding domain to the regulatory domain in *E. coli*. The polypeptide chain produced from the DNA fragment expected from the PCR is shorter by 197 or 188 corresponding amino acids than the full 3-phosphoglycerate-dehydrogenase. The shortest deletion is produced by the primer *serA* $\Delta$ 79-r (5'-GGATCCTTAATCCAGGCCACGGCCATT-3') and cuts out the region of 79 amino acids which has the greatest similarity to the regulatory domain of *E. coli*. In addition in all of the reverse complementary primers, which give rise to a shortened protein, behind the restriction site, the stop code TAA is introduced.

The PCR reaction is carried out over 30 cycles in the presence of 200  $\mu$ M deoxynucleotide-triphosphates (dATP, dCTP, dGTP, in an amount of 1  $\mu$ M of the corresponding oligonucleotides, 100 ng chromosomal AND from *corynebacterium glutamicum* ATCC13032,

1/10 volumes of 10 fold reaction buffers and 2.6 units of heat stabilized Tag-/Pwo-DNA-polymerase mixture (Expand High Fidelity PCR System of the Firm Roche Diagnostics, Mannheim, Germany) in a thermocycle (PTC-100 MJ Research, Inc., Watertown, USA) under the following conditions: 94°C for 60 seconds, 50°C for 90 seconds and 72°C for 2 minutes.

Following the PCR reaction, the obtained DNA fragments are isolated with the QIAExII gel extraction kit (Qiagen) in accordance with the conditions of the manufacturer, from 0.8% agarose gel and cloned blunt-end with the aid of the Sure Clone Kits (Amersham Pharmacia Biotech) in the *Sma*I restriction site of the vector pUC18. The plasmid is tested by restriction mapping for accuracy. This cloning was carried out in the *Escherichia coli* strain DH5 $\alpha$ mc<sup>r</sup> (Grant et al., Proceedings of the National Academy of Sciences of the United States of America USA (1990) 87: 4645-4649).

Then the *serA*-gene and *serA*-deletion construct were cloned in the *E. coli*/C glutamicum swing vector pZ1 (Menkel E. Thierbach G. Eggeling L. Sahm H., 1989, *Appl Environ Microbiol* 55(3): 684-688. The vector enabled the kanamycin resistance. The inserts of the deletion construct were respectively cut out by the restriction enzymes *Eco*RI and *Bam*HI from the pUC18 vector. The overhanging DNA ends were filled by means of a Klenow treatment and the fragments were ligated blunt end in the *Sca*I-cleaved vector

pZ1. The so obtained constructs were named pZiserA (FIG. 3), pZiserA $\Delta$ 79 (FIG. 4), pZiserA $\Delta$ 188 (FIG. 5), pZiserA $\Delta$ 197 (FIG. 6), pZiserA $\Delta$ 205 (FIG. 7) and pZiserA $\Delta$ 211 (FIG. 8).

2. Overexpression of the Wild Type *serA*-Gene and the  
5 Foreshortened *serA*-Allele in *C. glutamicum*

The plasmids pZiserA, pZiserA $\Delta$ 79, pZiserA $\Delta$ 188),  
pZiserA $\Delta$ 197, pZiserA $\Delta$ 205 and pZiserA $\Delta$ 211 were introduced by  
electroporation individually into *C. glutamicum*. As a control, the  
10 media plasmid pZ1 was also electroporated into *C. glutamicum* ATCC  
13032. The thus obtained strains 13032pZ1, 13032pZ1serA,  
13032pZiserA $\Delta$ 79, 13032pZiserA $\Delta$ 188, 13032pZiserA $\Delta$ 197,  
13032pZiserA $\Delta$ 205 and 13032pZiserA $\Delta$ 211 were analyzed for  
overexpression of the 3-phosphoglycerate-dehydrogenase by means of  
15 the 3-phosphoglycerate-dehydrogenase enzyme test. For this purpose  
the six strains were activated in complex medium (CgIII = 2.5 g  
NaCl, 10 g bacto-peptone, 10 g bacto-yeast extract, pH 7.4 with 2%  
glucose) and the minimal medium CGXII and each was separately  
seeded from the preculture. The medium was identical with the  
20 medium CGXII described by Keilhauer et al (Journal of Bacteriology  
(1993) 175: 5593-5603) but containing additionally 25  $\mu$ g/mL of  
kanamycin. The composition of the medium described by Keilhauer is  
given in Table 1.

Table 1: Composition of the Medium CGXII

Components	Concentration
$(\text{HN}_4)_2\text{SO}_4$	20 g/L
Urea	5 g/L
$\text{KH}_2\text{PO}_4$	1 g/L
$\text{K}_2\text{HPO}_4$	1 g/L
$\text{MgSO}_4 \times 7 \text{ H}_2\text{O}$	0.25 g/L
3-Morpholinopropansulfanic acid	42 g/L
$\text{CaCl}_2$	10 mg/L
$\text{FeSO}_4 \times 7 \text{ H}_2\text{O}$	10 mg/L
$\text{MnSO}_4 \times \text{H}_2\text{O}$	10 mg/L
$\text{ZnSO}_4 \times 7\text{H}_2\text{O}$	1 mg/L
$\text{CuSO}_4$	0.2 mg/L
$\text{NiCl}_2 \times 6 \text{ H}_2\text{O}$	0.02 mg/L
Biotin	0.2 mg/L
Glucose	40 g/L
Protocatechuic acid	30 mg/L

The cells were harvested in the exponential growth phase at  $\text{OD}_{600}$  of 5 to 8 and washed twice in 100 mM Tris-HCl, pH 7.5. The cell pellets were then frozen at  $-20^\circ\text{C}$  until disintegration. The frozen cell pellets were moisturized on ice and resuspended with 2 ml cold Tris-HCl pH 7.5/10% glycerine in a Brenson sonifier for 10 minutes. Then the cell fragments were separated by centrifugation at 13000 rpm and  $4^\circ\text{C}$  in a Sigma -202 MK centrifuge. The thus



obtained supernatant is desalted as a raw extract initially on a PD-10 column using the conditions set by the manufacturer (Amersham Pharmacia Biotech) and then immediately subjected to enzyme measurement. The enzyme test relied upon the photometric detection of the formation of NADH in the reaction of 3-phosphoglycerate and NAD to NADH. The test composition is shown in Table 2.

Table 2: Components of the Test composition in Determination of the 3-Phosphoglycerate-Dehydrogenase Activity

	<u>Original Solution</u>	<u>End Concentration</u>
10 Tris-HCl: pH 8.8	500 mM	100 mM
Dithiothreite	100 mM	1 mM
EDTA	500 mM	5 mM
Hydrazine	250 mM	10 mM
NAD	20 mg/ml	2 mg/ml
15 RE	ca. 2 mg/ml	ca. 200 µg protein
<u>3-phosphoglycerate</u>	<u>150 mM</u>	<u>15 mM</u>

With these test results a specific activity of about 150 mU/mg protein can be determined for the wild-type 3-phosphoglycerate-dehydrogenase activity. It was found that the overexpression of the complete *serA* gene gave about a 16-fold increase in the specific 3-phosphoglycerate-dehydrogenase activity. The construct *serA*Δ197 gives a 10-fold overexpression with respect to the wild type protein. The constructs *serA*Δ188 and *serA*Δ205

allow a 3 to 3.4 fold overexpression whereas for the constructs *serA*Δ205 and *serA*Δ79 only a 1.2 to 1.5 fold overexpression is possible. Thus it has been shown that through deletion of the C-terminal 197 amino acids of 3-phosphoglycerate-dehydrogenase from *C. glutamicum* produced mutant *serA*Δ197 is functional and has more than 60% of the wild type activity.

In Table 3 the results have been collected.

Table 3: Overexpression of the *serA* gene and the C-terminal foreshortened *serA* allele.

Line	Specific PGD Activity [U/mg Protein]	Factor of Overexpression
13032pZ1	130	1.0
13032pZ1 <i>serA</i>	2140	16.5
13032pZ1 <i>serA</i> Δ79	190	1.5
13032pZ1 <i>serA</i> Δ188	440	3.4
13032pZ1 <i>serA</i> Δ197	1320	1.5
13032pZ1 <i>serA</i> Δ205	390	3.0
13032pZ1 <i>serA</i> Δ211	150	1.2

\*The 3-phosphoglycerate-dehydrogenase activity in line 13032pZ1 was normalized to 1.0.

3. Investigation of the Inhibition of the Wild Type 3-Phosphoglycerate-Dehydrogenase of *C. glutamicum* and the C-terminal Foreshortened Mutant *serA*Δ197 by L-Serine

In the following tests were made whether the C-terminus foreshortened mutant *serA*Δ197 was no longer blocked by L-serine. For that purpose initially the inhibition of the 3-phosphoglycerate-dehydrogenase of the wild type was investigated in cell-free extracts of *C. glutamicum* by L-serine based upon the above described enzyme tests. For that purpose to the test bath were added 1, 5 and 10 mM L-serine and were incubated for 5 minutes at 30°C. The reaction was then started by the addition of 15 mM 3-phosphoglycerate-dehydrogenase. The incubation was necessary in order to be able to detect an inhibition (Table 4). This time dependency of the L-serine inhibition which required several minutes of incubation before a constant level of inhibition was reached has also been described for other 3-phosphoglycerate-dehydrogenase, for example for the purified enzyme of *B. subtilis* (Saski R. and Pitzer L., 1975, Eur. J. Biochem., 51:415-427).

Table 4: Inhibition of the Wild Type 3-Phosphoglycerate-Dehydrogenase of *C. glutamicum* by L-Serine

L-Serine [mM]	Relative 3- Phosphoglycerate-Dehydrogenase Activity [%]	
	Without Incubation	5 Minute Incubation at 30°C
0	100*	100*
1	106	96
5	112	82
10	104	56

\* The activity of the 3-phosphoglycerate-dehydrogenase was set at 100% addition of L-serine.

Building on these results, the L-serine inhibition 3-phosphoglycerate-dehydrogenase in the 13032pZ1serA and 13032pZ1serAΔ197 lines was explored. It was found that indeed, the C-terminal foreshortened 3-phosphoglycerate-dehydrogenase mutant no longer was significantly limited by L-serine (Table 5).

Table 5: Inhibition of the Overexpressed 3-phosphoglycerate-dehydrogenase by L-serine in the strains 13032pZ1serA and 13032pZ1serAΔ197

Relative 3- Phosphoglycerate-Dehydrogenase		
L-Serine	Activity [%] **	
[mM]	13032pZ1serA	13032pZ1serA $\Delta$ 197
0	100*	100*
10	34	95

\* The activity of the 3-phosphoglycerate-dehydrogenase was set at 100% addition of L-serine.

\*\* Determination of the activity after 5 minutes of incubation at 30°C with and without L-serine.

Thus it was found that the generation of a deregulated 3-phosphoglycerate-dehydrogenase mutant in a targeted way by deletion of the C-terminus of the 3-phosphoglycerate-dehydrogenase from *C. glutamicum* was successful.

#### 4. Increased Accumulation of L-Serine by Overexpression of the Gene for the Deregulated 3-Phosphoglycerate-Dehydrogenase (serA $\Delta$ 197)

For analysis of the L-serine production by the line with deregulated 3-phosphoglycerate-dehydrogenase, the plasmids pZ1, pZ1serA and pZ1serA $\Delta$ 197 in the strain *Corynebacterium glutamicum* 13032 $\Delta$ panBC was transformed (E. Radmacher, A. Vaitsikova, U. Burger, K. Krumbach, H. Sahm, L. Eggeling, 2002, Appl. Environ. Microbiol. (Publication in preparation)). This line is auxotrophic as to pantothenae through the deletion of the pantothenate by

synthesis genes *panB* and *panC* and is distinguished in that under pantothenate limitation, it produces because of an increased accumulation of pyruvate, about 50 mM alanine and 8 mM valine. In addition, the strain forms about 100  $\mu$ M L-serine and is suitable as a starting strain for the construction of a L-serine producing strain. The strain with the plasmid pZ1serA was deposited in accordance with the Budapest agreement on 11 April 2002 with the DSMZ under the DSM No. 14922.

To explore the L-serine production the three lines were cultured in complex medium (CgIII with 2% glucose and with 50  $\mu$ g/1 kanamycin) and the fermentation medium CGXII (J Bacteriol (1993) 175: 5595-5603) each seeded from the preculture. The medium contained additional 50  $\mu$ g/1 kanamycin and 1  $\mu$ M pantothenate. Two independent fermentations were carried out. After cultivation for 24 or 25 hours at 30°C on a rotation shaker operating at 120 rpm, the L-serine quantity accumulated in the medium was determined. The determination of the amino acid concentration was effected by high pressure liquid chromatography. (J Chromat (1983) 266: 471-482). The results of the fermentation are given in Table 6 and show that even the overexpression of the wild type *serA* gene can give rise to about 10% increase in the L-serine accumulation in the medium. The overexpression of the deregulated 3-phosphoglycerate-dehydrogenase produces by comparison an increase of up to 40% with respect to the control line which only contained the empty plasmid. Thus the use of the constructed and described gene for the

deregulated L-serine biosynthesis enzyme 3-phosphoglycerate-dehydrogenase supported a process which significantly improved the L-serine formation.

Table 6: Accumulation of L-Serine in the Culture  
Supernatant of *Corynebacterium glutamicum* 13032 $\Delta$ panBC  
after Expression of Gene *serA* or *serA* $\Delta$ 197

Line	t [h]	TG [mg/ml]	L- Serine [ $\mu$ M]	L- Serine/TG [mg/g]
10 13032DpanBCpZ1	24	18.3	164	0.9
13032DpanBCpZ1 <i>serA</i>	24	14.7	163	1.2
13032DpanBCpZ1 <i>serA</i> $\Delta$ 197	24	16.5	199	1.3
* TG = Cell dry weight				